Skip to content

Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones

A Randomized Controlled Trial of Direct Noise Reduction in the ICU Using Overnight Application of In-ear Earplugs or In-ear Earplugs Plus Noise-Canceling Headphones to Reduce the Incidence and Duration of ICU Delirium

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01343095
Enrollment
8
Registered
2011-04-27
Start date
2011-05-31
Completion date
2015-06-30
Last updated
2018-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium, Sleep Fragmentation

Keywords

ICU Delirium, Delirium, Sleep Quality, Sleep Efficiency, ICU Noise, Noise Reduction, Earplugs, Noise Canceling Headphones

Brief summary

This study seeks to examine the effects of overnight noise reduction in critically ill patients who are receiving mechanical ventilation. The investigators will randomly place subjects into one of three groups: 1) usual care 2) overnight earplugs 3) overnight earplugs and noise-canceling headphones. The investigators will monitor for safety, and will measure the amount of delirium experienced by subjects, record the amount of sedating and painkilling medicines required, and measure sleep quality during the study, among other information. The investigators will also measure noise levels experienced by patients in each group. The investigators predict that the use of overnight noise reduction will be safe and will reduce the amount of delirium by improving the quality of sleep in critically ill patients.

Detailed description

Delirium is an acute confusional state defined by fluctuating mental status, inattention, and either disorganized thinking or an altered level of consciousness. Acute delirium is an increasingly recognized problem in intensive care units (ICUs) in the US and worldwide. ICU Delirium has been estimated to occur in as many as 50 to 80 percent of ICU patients. Delirium in the ICU has been associated with worsened clinical outcomes such as prolonged hospitalization and death \[1-4\]. Although noise has been shown to negatively influence sleep in the ICU, and sleep disturbance is a recognized contributor to ICU delirium\[1-2, 4\], there is no well-established link between ICU noise levels and the development of ICU delirium. Optimal strategies for the prevention and treatment of ICU delirium are yet to be defined, and this study will focus on a novel noise-reduction approach which has potential to impact both prevention and treatment \[5-8\]. Findings will be generalizable to other tertiary care medical intensive care units caring for adult patients. Objectives Our multidisciplinary team will evaluate the safety and feasibility of direct noise reduction in the Wake Forest University Baptist Medical Center (WFUBMC) Medical Intensive Care Unit (MICU), and any effect on the incidence of ICU delirium. Methods and Measures Design * Forty-five (45) patients receiving mechanical ventilation will be randomized to receive either passive direct noise reduction (earplugs), both passive and active direct noise reduction (earplugs and noise-canceling headphones), or no direct noise reduction (usual practice). * Ambient noise levels and the reduction in noise accomplished by direct noise reduction will be measured according to standardized audiometric techniques. * Sleep structure, including amount of recovery sleep, will be measured over one night according to standardized polysomnographic (sleep study) techniques * The incidence of delirium will be assessed as well as multiple other endpoints including but not limited to amount of psychoactive medication prescribed and amount of physical restraints required.

Interventions

DEVICEFoam Earplugs

Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)

DEVICENoise Canceling Headphones

Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.

Sponsors

Wake Forest University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients who are admitted to our MICU for at least 24 hours with at least 72 hours' additional expected stay in ICU, and who are mechanically ventilated

Exclusion criteria

* severe to profound hearing loss * baseline use of hearing aids * eardrum perforation * severe cerumen impaction * head or oromaxillofacial trauma * external ventricular drain or intracranial pressure monitoring devices * comatose patients who are deemed by their attending physician as unlikely to awaken within 72 hours * patient status as comfort-measures only * any other contraindication to the use of earplugs or headphones

Design outcomes

Primary

MeasureTime frame
Days Free of Delirium or ComaDuring the Study Period (Study Days 0-7 while patients were in ICU)

Secondary

MeasureTime frameDescription
Noise AttenuationOvernight (10pm-6am) on study day 2 or 3.The reduction in noise experienced by the subject when using the study intervention.
Sleep Efficiency and ArchitectureOvernight (10pm-6am) on study day 2 or 3Staging of sleep with efficiency determined as a ratio of total sleep time/total study time.
Amount of Sedative Use (Midazolam and Lorazepam)During the Study Period (Study Days 0-7)
Amount of Analgesic UseDuring the Study Period (Study Days 0-7)Mean of analgesic daily use
Amount of Sedative Use (Propofol and Demedetomidine )During the Study Period (Study Days 0-7)Mean of sedative daily use (Propofol and Demedetomidine )

Countries

United States

Participant flow

Participants by arm

ArmCount
Usual Care
Usual Care between 10pm-6am
2
Earplugs
Application of earplugs from 10pm-6am nightly for seven nights or until ICU discharge. Foam Earplugs: Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
3
Earplugs and Headphones
Earplugs and Noise-canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge. Foam Earplugs: Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer) Noise Canceling Headphones: Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
3
Total8

Baseline characteristics

CharacteristicUsual CareEarplugsEarplugs and HeadphonesTotal
Age, Continuous72 years66 years56 years63 years
Mean SAPS II57.5 units on a scale40 units on a scale57.6 units on a scale51 units on a scale
Region of Enrollment
United States
2 participants3 participants3 participants8 participants
Sex: Female, Male
Female
0 Participants3 Participants2 Participants5 Participants
Sex: Female, Male
Male
2 Participants0 Participants1 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 20 / 30 / 3
other
Total, other adverse events
0 / 20 / 30 / 3
serious
Total, serious adverse events
0 / 20 / 30 / 3

Outcome results

Primary

Days Free of Delirium or Coma

Time frame: During the Study Period (Study Days 0-7 while patients were in ICU)

ArmMeasureValue (MEAN)
Usual CareDays Free of Delirium or Coma0.5 days
EarplugsDays Free of Delirium or Coma2.3 days
Earplugs and HeadphonesDays Free of Delirium or Coma2 days
Secondary

Amount of Analgesic Use

Mean of analgesic daily use

Time frame: During the Study Period (Study Days 0-7)

ArmMeasureGroupValue (MEAN)
Usual CareAmount of Analgesic UseFentanyl0.29 mg
Usual CareAmount of Analgesic UseMorphine0 mg
Usual CareAmount of Analgesic UseDilaudid0 mg
Usual CareAmount of Analgesic UseHydrocodone0 mg
EarplugsAmount of Analgesic UseHydrocodone0 mg
EarplugsAmount of Analgesic UseFentanyl0.37 mg
EarplugsAmount of Analgesic UseDilaudid0 mg
EarplugsAmount of Analgesic UseMorphine0 mg
Earplugs and HeadphonesAmount of Analgesic UseHydrocodone0.18 mg
Earplugs and HeadphonesAmount of Analgesic UseMorphine0.03 mg
Earplugs and HeadphonesAmount of Analgesic UseDilaudid0.07 mg
Earplugs and HeadphonesAmount of Analgesic UseFentanyl0.32 mg
Secondary

Amount of Sedative Use (Midazolam and Lorazepam)

Time frame: During the Study Period (Study Days 0-7)

ArmMeasureGroupValue (MEAN)
Usual CareAmount of Sedative Use (Midazolam and Lorazepam)Midazolam5 mg
Usual CareAmount of Sedative Use (Midazolam and Lorazepam)Lorazepam0.21 mg
EarplugsAmount of Sedative Use (Midazolam and Lorazepam)Midazolam10.65 mg
EarplugsAmount of Sedative Use (Midazolam and Lorazepam)Lorazepam0.40 mg
Earplugs and HeadphonesAmount of Sedative Use (Midazolam and Lorazepam)Midazolam9.22 mg
Earplugs and HeadphonesAmount of Sedative Use (Midazolam and Lorazepam)Lorazepam0.39 mg
Secondary

Amount of Sedative Use (Propofol and Demedetomidine )

Mean of sedative daily use (Propofol and Demedetomidine )

Time frame: During the Study Period (Study Days 0-7)

ArmMeasureGroupValue (MEAN)
Usual CareAmount of Sedative Use (Propofol and Demedetomidine )Demedetomidine1.36 mcg/kg
Usual CareAmount of Sedative Use (Propofol and Demedetomidine )Propofol0 mcg/kg
EarplugsAmount of Sedative Use (Propofol and Demedetomidine )Propofol0 mcg/kg
EarplugsAmount of Sedative Use (Propofol and Demedetomidine )Demedetomidine0.98 mcg/kg
Earplugs and HeadphonesAmount of Sedative Use (Propofol and Demedetomidine )Propofol0 mcg/kg
Earplugs and HeadphonesAmount of Sedative Use (Propofol and Demedetomidine )Demedetomidine0 mcg/kg
Secondary

Noise Attenuation

The reduction in noise experienced by the subject when using the study intervention.

Time frame: Overnight (10pm-6am) on study day 2 or 3.

Population: Devices were unable to measure noise above 85 dB(A) from the in-ear location; no noise data was collected.

Secondary

Sleep Efficiency and Architecture

Staging of sleep with efficiency determined as a ratio of total sleep time/total study time.

Time frame: Overnight (10pm-6am) on study day 2 or 3

Population: Sleep measurement equipment was not available for use during the study period

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026